Clinical Trial Update: Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB [Phase 3]

View source ↗

Summary

Phase 3 clinical trial in metastatic colorectal cancer comparing FOLFIRI plus cetuximab versus bevacizumab, using tissue RAS/BRAF wild-type and liquid biopsy RA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)

Snippet

Sponsor: Azienda USL Reggio Emilia - IRCCS | Conditions: Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Status: RECRUITING